| Symbol | MREO |
|---|---|
| Name | MEREO BIOPHARMA GROUP PLC |
| Sector | HEALTH CARE |
| Region | Europe |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 4TH FLOOR,ONE CAVENDISH PLACE, LONDON, W1G 0QF, United Kingdom |
| Telephone | +44 333 - 023-7300 |
| Fax | — |
| — | |
| Website | https://www.mereobiopharma.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001719714 |
| Description | Mereo BioPharma Group PLC is a multi-asset, clinical-stage biopharmaceutical company. It is focused on the development and commercialization of innovative therapeutics that aim to improve outcomes for oncology and rare diseases. Its lead oncology product candidate is etigilimab, for patients with advanced solid tumors. Some of the other products in the pipeline are setrusumab, alvelestat, leflutrozole, navicixizumab, and acumapimod. Additional info from NASDAQ: |
New Form SCHEDULE 13G/A - Mereo BioPharma Group plc <b>Filed:</b> 2026-05-15 <b>AccNo:</b> 0000935836-26-000265 <b>Size:</b> 16 KB
Read moreNew Form SCHEDULE 13G - Mereo BioPharma Group plc <b>Filed:</b> 2026-05-14 <b>AccNo:</b> 0000070858-26-000293 <b>Size:</b> 171 KB
Read more(99% Neutral) MEREO BIOPHARMA GROUP PLC (MREO) Announces Regulatory Update
Read moreMereo BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates
Read more(10% Negative) MEREO BIOPHARMA GROUP PLC (MREO) Reports Q2 2026 Financial Results
Read moreMereo BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates
Read moreNew Form 8-K/A - Mereo BioPharma Group plc <b>Filed:</b> 2026-05-12 <b>AccNo:</b> 0001193125-26-218290 <b>Size:</b> 446 KB <br />Item 2.02: Results of Operations and Financial Condition <br />Item 9.01: Financial Statements and Exhibits
Read moreNew Form ARS - Mereo BioPharma Group plc <b>Filed:</b> 2026-04-09 <b>AccNo:</b> 0001193125-26-148835 <b>Size:</b> 1 MB
Read moreNew Form DEF 14A - Mereo BioPharma Group plc <b>Filed:</b> 2026-04-09 <b>AccNo:</b> 0001193125-26-148832 <b>Size:</b> 5 MB
Read moreMREO FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Mereo BioPharma (MREO) Investors of Securities Class Action Deadline on April 6, 2026
Read more